Back to the drawing board for Sumitomo’s deal-making
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Big hitters eye Sjögren’s syndrome white space
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
Why investors should question Savara's excuse
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
Takeda casts doubt on the remaining approach to amyloidosis
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
Hard knocks for brain cancer, again
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
Vistagen tries not to get depressed despite bad omens
A flop in a small depression trial hits Vistagen Therapeutics, but the group insists that all is well ahead of its main event.
Rose-tinted glasses might not save Genkyotex
Genkyotex has dredged the data to find a glimmer of hope with GKT831 in primary biliary cholangitis, but cash is running short.
EASL 2019 – Research reminds hep B bulls that progress will be slow
Presentations from Assembly Biosciences and Spring Bank Pharmaceuticals could disappoint those hoping to see more definitive steps towards a functional cure for hepatitis…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.